Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belapectin - Galectin Therapeutics

Next Previous
Drug Profile

Belapectin - Galectin Therapeutics

Alternative Names: Galactoarabino-rhamnogalaturonate; GR MD 02

Latest Information Update: 31 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galectin Therapeutics
  • Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies; Small molecules
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer

Highest Development Phases

  • Phase II/III Liver cirrhosis
  • Phase II Atopic dermatitis; Hepatic fibrosis; Plaque psoriasis
  • No development reported Breast cancer; Cardiac-arrhythmias; Diabetic nephropathies; Fibrosis; Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer; Prostate cancer; Pulmonary arterial hypertension; Pulmonary fibrosis; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 19 Dec 2025 Galectin Therapeutics plans a follow up type C neeting with the US FDA regarding the planned clinical trial for belapectin
  • 19 Dec 2025 The US FDA provides a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request regarding the development program for belapectin
  • 19 Dec 2025 Galectin Therapeutics plans a phase III trial for Liver cirrhosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top